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ABSTRACT
Background: Antiepidermal growth factor receptor
(EGFR)-targeted therapy is widely used in many
epithelial cancer types. We investigated lapatinib effects
on cutaneous squamous cell carcinoma (cSCC)
scheduled for resection and in coexisting precursor
lesions (actinic keratosis (AK) and Bowen’s disease
(BD)) in a phase 2 mode of action clinical trial
including a histological workup of the cSCC.
Patients and methods: We initiated a prospective
single-centre, open-label, non-controlled clinical study
with translational intentions to investigate changes in
size and histopathological features in cSCC after a
14-day period of neoadjuvant lapatinib therapy at
a dose of 1500 mg/day prior to surgery, to quantify the
impact on AK and BD in the same patient after 56 days
and to evaluate the tolerability in patients with cSCC
and precursor lesions.
Results: 10 immunocompetent male patients were
included with a mean age of 73 years (range 59–87).
8 patients were treated with the study medication
lapatinib 1500 mg/day for a total duration of 56 days
according to the protocol and were available for full
analysis, whereas 2 patients had to discontinue
treatment during the first 2 weeks because of adverse
events (diarrhoea, pancreatitis). Tolerability was
acceptable with only 1 related grade III adverse event.
A reduction in tumour size of cSCC was documented
in 2 of 8 evaluable patients after 14 days of treatment.
The mean regression of captured precursor lesions
was 30% after 56 days of treatment and 36% 28 days
after therapy cessation.
Conclusions: Short-term lapatinib resulted in a cSCC
tumour reduction in 2 of 8 patients. In addition, there
was a clinically documented reduction of AK in 7 of 8
patients encouraging larger clinical trials, especially in
high-risk patients with cSCC such as organ transplant
recipients.
Trial registration number: NCT0166431.
INTRODUCTION
Cutaneous squamous cell carcinoma (cSCC)
is the second most common skin cancer
with rising incidence associated with high
cumulative ultraviolet light exposure.1
Immunosuppressed patients, such as organ
transplant recipients (OTR) or patients with
lymphoma/leukaemia, have a higher risk
for the development of cSCC and their pre-
cursor lesions.2
The number of patients with nodal and
distant metastases, as well as locally advanced
cSCC, remains unclear. Factors associated with
aggressive behaviour and metastatic potential
of cSCC include anatomical site, tumour size
(diameter >2 cm) and depth, histological dif-
ferentiation and host-immunosuppression.3
Surgical treatment is the standard treatment
for the majority of invasive cSCC.4 5 Irradiation
therapy is reserved for patients over 60 years.4–6
Systemic treatment options for locally
advanced or metastasising SCC comprise cis-
platin, doxorubicin, 5-ﬂuorouracil, bleomycin,
methotrexate, interferon and combination
therapies. Response rates vary widely from 17%
to 78%, but data are scarce.7
The epidermal growth factor receptor
(EGFR) and its associated signalling pathways
Key questions
What is already known about this subject?
Antiepithelial growth factor receptor (EGFR) antibodies
have been successfully used in patients with cutane-
ous squamous cell carcinomas (SCC). EGFR targeting
kinase inhibitors have not been studied as yet.
What does this study add?
The use of the EGFR inhibitor lapatinib resulted in
regressions of SCC in the neoadjuvant setting and
improvement of SCC precursor lesions.
How might this impact on clinical practice?
In high-risk patients with SCC such as organ trans-
plant recipients, EGFR inhibitors should be investi-
gated as a chemopreventive strategy.
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have been implicated in the development of SCC.8 9
EGFR is targeted by EGFR-monoclonal antibodies
(EGFRab), such as cetuximab and panitumumab, and
small-molecule tyrosine kinase inhibitors, such as
erlotinib, lapatinib and geﬁtinib. Either approach
aims to interrupt signal transduction downstream of
the EGFR and results in the arrest of tumour prolifer-
ation.10 11 The human EGFR family encompasses four
receptor tyrosine kinases (ErbB1/EGFR, ErbB2/
HER2, ErbB3, ErbB4). Each receptor has an extracel-
lular domain, a hydrophobic transmembrane and an
intracellular domain, which contains a protein tyro-
sine kinase. Seven ligands bind to EGFR including
the epidermal growth factor (EGF) and transforming
growth factor β (TFGβ), none binds to ErbB2, two
bind to ErbB3, and seven bind to ErbB4. The PI3K
kinase is a major intracellular target of EGFRs, result-
ing in an activation of Akt kinase, which then phos-
phorylates mechanistic target of rapamycin and can
provide many signals, important for proliferation and
survival of malignant cells.12 13 Small kinase inhibi-
tors are poorly studied in cSCC and their precursor
lesions. Therefore, we investigated lapatinib in cuta-
neous squamous neoplasias.
Lapatinib is an orally active, low molecular weight,
dual tyrosine kinase inhibitor targeting two members of
the HER family receptors HER1 and HER2/c-neu.14 It
acts intracellularly by blocking the cytoplasmic
ATP-binding site of the kinase domain, inhibiting phos-
phorylation and receptor activation. This inhibits various
downstream signalling cascades, including the phospha-
tidylinositol 3-kinase/Akt (PKB) and the Ras/Raf/
MEK/ERK1/2 pathways. Lapatinib’s advantage in com-
parison with other EGFR-targeted drugs is its small size
and interference with more than one member of the
HER family. Consequently, lapatinib is expected to sup-
press cancer cell growth more effectively than monotar-
get tyrosine kinase inhibitors.15 16
EGFRab-targeted therapy is used for the treatment of
advanced cSCC with a response rate of 28–64%, either
in combination with radiotherapy or as a single agent.17
To the best of our knowledge, lapatinib has not yet been
investigated in cSCC.
We conducted a pilot study to determine the impact
of oral treatment with the EGFR-antagonist lapatinib on
cSCC and the coexisting actinic keratosis (AK) and
Bowen’s disease (BD).
METHODS
Study design
Some ﬁnancial support and the drug was assured by
Glaxo Smith Kline (GSK).
The study design was a single-centre, investigator-
initiated, open-label study (ﬁgure 1A). We included
patients with advanced cSCC with concomitant AK or
BD. All patients were informed about the investigative
nature of this treatment and signed a written informed
consent in accordance with the local institutional board
and guidelines.
The primary objective was to evaluate the tumour
response macroscopically in patients with primary cuta-
neous SCC lesions after 14 days of oral treatment, to
investigate the histological features of regressive cSCC
and to demonstrate the impact of the therapy on con-
comitant in situ lesions such as AK or BD. The second-
ary objective was to evaluate the tolerability of lapatinib
therapy in patients with cSCC.
Eligibility
Patients with non-metastasising cSCC (at an age over 18)
who were amenable to surgical resection were eligible.
The diagnosis of histologically conﬁrmed cSCC stage
Tis-T2N0 was necessary for inclusion in the study with a
minimum of two coexisting in situ lesions. Patients were
required to have a performance status of 0 or 1 accord-
ing to Eastern Cooperative Oncology Group (ECOG)
and adequate organ system functions deﬁned by labora-
tory assessment and echocardiography. Patients with
active hepatic or biliary disease, with any anticancer
therapy 14 days prior to the ﬁrst dose of lapatinib or any
topical therapy of AK <4 weeks prior to study initiation,
were excluded.
Treatment
All patients received the study drug lapatinib at a
dose of 1500 mg taken orally once daily for a total
duration of 56 days (ﬁgure 1A). Patients were
instructed to take lapatinib at least 1 h before or at
least 1 h after meals. In order to gain insight into the
mechanism of tumour regression induced by lapati-
nib, the primary tumour was excised 14 days after
treatment start as it would have been done outside
the clinical trial.
Study evaluation and follow-up
All patients underwent a complete medical history and
physical examination within 14 days prior to treatment
start. Evaluation of cardiac ejection fraction by echocar-
diogram and ECG were performed before study enrol-
ment. A biopsy of the primary tumour for histological
conﬁrmation of cSCC clinical diagnosis was done during
screening. Diagnosis of AK and BD was made clinically.
Surgical excision of cSCC had to be performed 14 days
after lapatinib initiation. Physical examinations and
laboratory assessments were scheduled on days 14, 56
and 84. Clinical assessment of the cSCC and the precur-
sor lesions was performed and photographs of all
involved sites were taken on every study visit. We ana-
lysed tumour response of all primary tumours as well as
of the coexisting AK or BD lesions by bi-dimensional
perpendicular measurement of macroscopic tumour
size, adding up the sum of the two diameters. Analysis of
tumour response was done for all lesions before surgical
excision on day 14 as well as by decrease of size in the at
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least two predeﬁned coexisting reference AK or BD
lesions present in the individual patient at day 56 and
on the follow-up visit at day 84.
Histopathology
In total, formalin ﬁxed parafﬁn-embedded (FFPE)
blocks with tumour samples from eight patients enrolled
Figure 1 (A) Study scheme graph. (B) Lapatinib effect on coexisting precursor lesions at 14 and 56 days under lapatinib
treatment as well as 28 days after end of treatment. (C) Immunohistology of a pretherapy left and post-therapy biopsy right.
(1) p53 identifies the malignant cell population. (2) pEGFR reduction in tumour cells suggest on-target activity of lapatinib. Note
that normal keratinocytes still present pEGFR immunoreactivity. (3) Immunoreactivity of Ki67 reflecting proliferation is also
reduced in malignant but not normal keratinocytes (see sebaceous gland epithelium) (AK, actinic keratosis; BD, Bowen’s
disease).
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in the trial were included in our histopathological evalu-
ation. Each biopsy needed to have a diameter of at least
4 mm to be included in the analysis. FFPE samples were
stained with H&E and various immunohistochemical
protocols before independent evaluation by two derma-
topathologists (RD and BM). Normal epithelium served
as a positive internal control.
Samples were stained using the heat-induced epitope
retrieval technique (HIER) as previously described.18
Unspeciﬁc Fc-receptor binding of antibodies was com-
pared to isotype-matched controls. Stainings were per-
formed on 4 μm sections counterstained with
haematoxylin using an AutostainerLink 48 (Dako).
The following antibiodies were used for immunohisto-
chemical protein expression analysis: to evaluate the acti-
vation of the EGF signalling pathway, anti-pEGFR clone
53A5 (Cat.Nr. 4407, Sell Signaling) and anti-HER2 clone
4B5 (Cat.Nr: 790–2991, Ventana) were used; to evaluate
the activation of the PI3K/AKT signalling pathway,
anti-AKT1 clone Y89 (Cat.Nr: ab32505, Abcam) and
anti-pAKT (Cat.Nr: ab8932, Abcam) were used; to evalu-
ate cell proliferation and UV-induced alterations in cell
cycle anti-Ki67 clone MIB-1 (Cat.Nr: M7240, Dako),
anti-p53 (Cat.Nr: E06125, Ventana) and anti-p16 clone
G175–405 (Cat.Nr: 550834, BD Pharmogen) were used.
Immunohistochemical scoring of positive cells was
graded as follows: 0–5%, no positive cells found in the
tumour area; 6–25% for low expression; 26–50% for
average expression, 51–75% for high expression and 76–
100% for very high expression of the tumour area.
Statistical analysis
Owing to the low patient numbers, statistical analysis was
performed using descriptive statistics. To compare
changes in lesion size, Student t test was used.
RESULTS
Patients
A total of 12 patients were screened from September
2012 to August 2013 and 10 patients were enrolled in
the study. All enrolled patients were Caucasians of male
gender. The mean age was 73 years (range 59–87).
Several patients suffered from concomitant diseases such
as diabetes mellitus, arterial hypertension, coronary or
hypertensive heart disease, rheumatic polymyalgia, car-
cinoma of the prostate and coeliac disease, etc. Except
for one patient, all patients had a history of previous
skin cancer. Two patients discontinued the study due to
adverse events: one after 2 weeks of lapatinib treatment
due to diarrhoea and abdominal pain related to the
study medication as grade 3 toxicity, and one due to an
acute pancreatitis, judged by the investigator as not
related to study medication. The follow-up examination
on day 84 (28 days after end of treatment) was per-
formed in eight patients who were treated with the study
medication lapatinib for 56 days.
Most common toxicities were diarrhoea (6/10
patients), the typical papulopustular rash reported for
EGFR and MEK inhibitors (6/10 patients) and fatigue
(5/10 patients).19 Two patients reported abdominal
pain, two olecranon bursitis, one reported nausea, one
loss of appetite and one mucositis of the oral mucosa.
There was only one related adverse event of grade 3
(diarrhoea), all other were mild adverse events of grades
1 and 2.
The localisation of the cSCC was on the head in six of
our included patients, on the leg in two patients and on
the trunk in two other patients. All of the patients had
at least two additional clinically diagnosed AK or BD
lesions (tables 1 and 2).
Macroscopic tumour evaluation
The median tumour size in the cSCC before treatment
initiation was 69 mm (range 26–350 mm, n=8). On the
day of surgical excision, 14 days after treatment start we
observed a reduction in tumour size in 2 of 8 primary
tumours with a tumour reduction of 16 mm (−42%),
and 160 mm (−54%), respectively. In 2 out of 8 cSCC,
we observed an increase in tumour size by 8 mm
(+16%) respectively 6 mm (+27%). In four of eight
patients, there was no change in tumour size (table 1).
In order to evaluate the effect on precursor lesions
such as AK and BD, we analysed the sum of all precursor
lesions in every patient after 56 days of treatment, as well
as 28 days after the end of treatment at the follow-up
visit (table 2). In seven of eight patients, we observed at
least a partial remission of precancerous lesions, with a
complete remission of 1 AK in two of eight patients
(ﬁgure 1B and ﬁgure 2) and a complete remission of
three AK in one patient. Only in one of eight patients,
there was no change in the number and size of the coex-
isting lesions. The mean percentage of the regression of
all precancerous lesions was 30% (range 0–87%) on day
56 and 36% (range 5–100%) on day 84 (table 2).
Histology and immunohistochemistry of pretreated and
post-treated cSCC samples
In a total of eight patients, excision of the primary
tumour was performed according to the study protocol
for a comparison of the pretreatment sample with the
Table 1 Size of cutaneous squamous cell carcinoma
(cSCC) by calculation of the sum of the perpendicular
diameter in mm
Size of cSCC in mm (%)
Patient Baseline Day 14
1 50 (100) 58 (116)
2 16 (100) 16 (100)
3 30 (100) 30 (100)
4 28 (100) 12 (43)
5 37 (100) 37 (100)
6 350 (100) 190 (54)
7 16 (100) 16 (100)
8 22 (100) 28 (127)
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resected tumours on day 14. The ﬁndings demonstrated
profound intraindividual differences.
As expected, all tumour samples showed increased
expression of the proliferation marker Ki67 and tumour
suppressor p53. Strong immunoreactivity for p16 (>50%
of the tumour cells were positive) was found in three
patients. Strong immunoreactivity for pAKT (>50% of
the tumour cells were positive) was detected in two
patients. Her2 was not expressed. In ﬁve of nine
patients, there was a strong immunoreactivity for pEGFR
(>50% of the tumour cells were positive).
A clear alteration in EGFR phosphorylation and in
proliferation reﬂected by Ki67 expression was found in
one biopsy pair. Corresponding stainings are shown in
ﬁgure 1C. All other stainings did not show profound dif-
ferences during therapy.
DISCUSSION
This study took advantage of the fact that clinical diag-
nosis of invasive cSCC is routinely conﬁrmed by
histology and patients who typically present concomi-
tant in situ lesions such as AK and BD and undergo
surgery a few weeks later. This allowed us to study
alterations in key cellular processes induced by lapati-
nib in cSCC by histology and immunohistochemistry
without additional biopsies, as well as to assess clinical
effects on AK and BD.
Clinically, we only observed a clear detectable shrink-
age in the cSCC of two patients. This low regression rate
might be due to the short 14-day treatment period
before resection. We did observe a notable change in
the palpable tumoural inﬁltration of the cSCC during
lapatinib treatment, which could not be captured by
macroscopic measurements. Furthermore, there was a
marked response in the coexisting precursor lesions
such as AK and BD after 2 months of treatment. Seven
patients presented a clear reduction of the size of AK. In
two patients, there was a complete clearing of one AK
(ﬁgure 1C), and in one patient we observed a complete
clearance of three AK. The 1-month follow-up after
treatment discontinuation per protocol revealed a
lasting clinical remission, as well as a further decrease of
the total lesion size in ﬁve patients (table 2). These
observations may suggest a possible antitumour efﬁcacy
for lapatinib in keratinocytic carcinomas.
Our patient cohort showed a relatively high expression
of pEGFR with positivity of >50% in ﬁve of eight evalu-
able patients. Fogarty et al20 found EGFR expression in 9
of 21 (43%) locally advanced cSCC with only ﬁve of
them expressing phosphorylated EGFR. In our stainings,
one biopsy pair supports the principle of lapatinib’s
Figure 2 Clinical response of actinic keratosis (AK) during
lapatinib treatment.
Table 2 Tumour size by sum of the perpendicular diameter in mm and percentage
Actinic keratosis and Bowen’s disease
Patient Baseline Day 56 Day 84
Number of
lesions
Size in mm
(%)
Number of
lesions
Size in mm
(%)
Number of
lesions
Size in mm
(%)
1 3 68 (100) 2 24 (35) 3 38 (56)
2 2 19 (100) 2 18 (95) 2 20 (105)
3 2 50 (100) 2 50 (100) 2 50 (100)
4 3 30 (100) 1 4 (13) 0 0 (0)
5 3 99 (100) 3 69 (70) 3 28 (28)
6 7 172 (100) 6 112 (65) 6 102 (59)
7 5 111 (100) 5 103 (93) 5 92 (83)
8 6 163 (100) 6 144 (88) 6 139 (85)
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value in patients with multiple AK. However, there is a
need for biomarkers to enrich for patients who would
beneﬁt from the treatment. Comparing pretreatment to
day 14 SCC tissue, there was one patient with a profound
downregulation of pEGFR and reduced proliferation.
The immunohistology results were very heterogeneous
from patient to patient, which supports the concept that
multiple signalling pathways are involved in UV-induced
carcinogenesis.
Two-month treatment was associated with acceptable
toxicity. There was no severe cardiac reaction in this
patient population of advanced age with several
comorbidities. Drug-related adverse reactions caused
treatment discontinuation in only one patient. Of note,
this patient had suffered from diarrhoea already before
and also after the 2 weeks off lapatinib exposure, sug-
gesting a pre-existing gastrointestinal problem. Adverse
effects of the skin are the most common adverse events
reported in treatment with EGFR inhibitors, followed by
diarrhoea. Development of rash, mostly papolopustular,
is a frequent problem in treatment with EGFR inhibi-
tors. Still, HER1/2 inhibition by lapatinib is known to
show a lower incidence of rash (41% of treated patients)
compared to HER1 inhibition with cetuximab, erlotinib
and panitumumab (75–90%).21 22 Diarrhoea in lapatinib
treatment is a frequent adverse event but is usually mild
(grade 1 or 2) and limited to a duration of 4–5 days.
Even if most studies report a favourable adverse effect
proﬁle of EGFR inhibitors including lapatinib, the cuta-
neous and gastrointestinal adverse reactions cause sig-
niﬁcant discomfort that would impact on the long-term
patient compliance. Lucchini et al23 describe a rate of
up to 33% of treatment discontinuation in patients
treated with EGFR inhibitors. Since epidermal growth
factor inhibitors have become the standard of care in
several solid malignancies, strategies for management of
a number of adverse events have been developed in the
past years.24
Drugs targeting EGFR have been approved for several
types of malignancy and are investigated in numerous
other tumour types, including advanced cSCC. At
present, no targeted therapy has been approved in
cSCC. Notably, one of the currently licensed indications
for anti-EGFR therapies is advanced SCC of the head
and neck (HNSCC). Several case reports and smaller
trials have shown a remarkable response in cSCC with
EGFR inhibitors such as cetuximab, geftinib and erloti-
nib.17 To the best of our knowledge, lapatinib has not
been used in treatment for cSCC so far, but several
phase II and III studies are under investigation for lapa-
tinib treatment in different HNSCC settings.12 25 26 In
our study, we choose a high dosage of lapatinib with
1500 mg/day as used in treatment for HNSCC. For
advanced cSCC and metastasised cSCC treatment,
options remain limited and are associated with high toxi-
cities. At the moment, anti-EGFR-targeted therapies are
the only option beyond radiotherapy and conventional
chemotherapeutics.
Furthermore, EGFR inhibition could beneﬁt patients in
the settings of primary and secondary prevention. There
is an unmet medical need in the highly prevalent condi-
tion of SCC of the skin. The need is highest in high-risk
groups such as OTR and in chronic lymphatic leukaemia
and for high-risk tumours such as SCC thicker than
5 mm. Also, patients with the occurrence of SCC with a
known high risk of metastasis (ie, tumour thickness above
5 mm, localisation on the ear or lips, histologically low dif-
ferentiation, perineural invasion, rapid growth, involve-
ment of regional lymph nodes) could beneﬁt from early
introduction of systemic EGFR inhibitors to slow or halt
the disease progression to distant metastasis.
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